RedHill Biopharma Ltd. [NASDAQ: RDHL] gained 9.16% or 0.09 points to close at $1.07 with a heavy trading volume of 4274940 shares. The company report on August 17, 2022 that RedHill Biopharma Announces EU Orphan Drug Designation for RHB-204 for NTM Infections.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
Developed as the first stand-alone standard of care first-line therapy for NTM disease caused by Mycobacterium avium complex (MAC) infection, RHB-204 is currently undergoing a Phase 3 study in the U.S.
EMA Orphan Drug Designation provides eligibility for 10 years post-approval EU market exclusivity. U.S. FDA Fast Track, Orphan and QIDP priority designations, previously granted to RHB-204, extend U.S. post-approval market exclusivity to a total of 12 years.
It opened the trading session at $1.05, the shares rose to $1.12 and dropped to $1.01, the range by which the price of stock traded the whole day. The daily chart for RDHL points out that the company has recorded -57.20% loss over the past six months. However, it is still -72.58% lower than its most recent low trading price.
If we look at the average trading volume of 2.96M shares, RDHL reached to a volume of 4274940 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about RedHill Biopharma Ltd. [RDHL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RDHL shares is $12.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RDHL stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for RedHill Biopharma Ltd. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on August 31, 2021. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on May 18, 2021, representing the official price target for RedHill Biopharma Ltd. stock.
The Average True Range (ATR) for RedHill Biopharma Ltd. is set at 0.08, with the Price to Sales ratio for RDHL stock in the period of the last 12 months amounting to 0.62.
Trading performance analysis for RDHL stock
RedHill Biopharma Ltd. [RDHL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 8.18. With this latest performance, RDHL shares gained by 9.28% in over the last four-week period, additionally sinking by -57.20% over the last 6 months – not to mention a drop of -84.52% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RDHL stock in for the last two-week period is set at 58.08, with the RSI for the last a single of trading hit 60.90, and the three-weeks RSI is set at 54.81 for RedHill Biopharma Ltd. [RDHL]. The present Moving Average for the last 50 days of trading for this stock 0.9030, while it was recorded at 1.0220 for the last single week of trading, and 2.0559 for the last 200 days.
RedHill Biopharma Ltd. [RDHL]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and RedHill Biopharma Ltd. [RDHL] shares currently have an operating margin of -94.61 and a Gross Margin at +42.39. RedHill Biopharma Ltd.’s Net Margin is presently recorded at -113.98.
Return on Equity for this stock declined to -860.29, with Return on Assets sitting at -54.12.
RedHill Biopharma Ltd.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 1.00.
An analysis of insider ownership at RedHill Biopharma Ltd. [RDHL]
There are presently around $4 million, or 12.60% of RDHL stock, in the hands of institutional investors. The top three institutional holders of RDHL stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 1,045,023, which is approximately 21.261% of the company’s market cap and around 12.96% of the total institutional ownership; DISCIPLINED GROWTH INVESTORS INC /MN, holding 810,646 shares of the stock with an approximate value of $0.87 million in RDHL stocks shares; and GAGNON SECURITIES LLC, currently with $0.4 million in RDHL stock with ownership of nearly 2.178% of the company’s market capitalization.
Positions in RedHill Biopharma Ltd. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 16 institutional holders increased their position in RedHill Biopharma Ltd. [NASDAQ:RDHL] by around 782,159 shares. Additionally, 20 investors decreased positions by around 1,412,254 shares, while 17 investors held positions by with 1,884,992 shares. The mentioned changes placed institutional holdings at 4,079,405 shares, according to the latest SEC report filing. RDHL stock had 4 new institutional investments in for a total of 404,349 shares, while 7 institutional investors sold positions of 197,681 shares during the same period.